Oxford BioDynamics (OBD) AI Stock Analysis

• Market Cap: £8.32M
• Dividend Yield: N/A
• Average Volume (3M): 26.19M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.63
• Revenue Growth: 45.22%
• EPS Growth: 55.71%
• Country: UK
• Employees: 51
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,957,577,600
• 10 Day Avg. Volume: 29,422,892
• 30 Day Avg. Volume: 26,187,473
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £0.50
• Price Target Upside: 19.05% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: 0.50p ▲(19.05% Upside)

Oxford BioDynamics' overall stock score is primarily impacted by its challenging financial performance, with continuous net losses and negative cash flows posing significant risks. While technical analysis shows some short-term bullish momentum, the negative P/E ratio and lack of dividend yield further weigh down the stock's attractiveness. The absence of earnings call and corporate events data limits additional insights.

Positive Factors

Revenue Growth

A strong revenue growth rate indicates increasing demand for OBD's biomarker tests, suggesting successful market penetration and potential for continued expansion in the biotechnology sector.

Proprietary Technology

The EpiSwitch® platform provides a competitive edge in biomarker identification, enhancing OBD's ability to offer unique, clinically relevant solutions, fostering long-term partnerships and revenue opportunities.

Strategic Collaborations

Strategic partnerships with industry leaders enhance market presence and facilitate revenue growth, providing a stable foundation for long-term business development and innovation in the biotechnology field.

Negative Factors

Financial Challenges

Persistent financial losses and cash flow issues indicate operational inefficiencies and may hinder the company's ability to invest in growth opportunities, posing a risk to long-term sustainability.

Rising Debt Levels

Increasing leverage and a rising debt-to-equity ratio suggest heightened financial risk, potentially limiting OBD's flexibility to navigate market challenges and invest in strategic initiatives.

Low Profit Margins

Low profit margins reflect operational inefficiencies and high costs relative to revenue, which may impede the company's ability to achieve profitability and sustain long-term growth in a competitive market.

Oxford BioDynamics Business Overview & Revenue Model

Company Description

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

How the Company Makes Money

Oxford BioDynamics generates revenue primarily through the sale of its biomarker tests and services, which are utilized by pharmaceutical companies, research institutions, and healthcare providers. The company's key revenue streams include fees for conducting epigenetic testing and analysis, licensing agreements for its proprietary technology, and collaborations with pharmaceutical companies for the development of companion diagnostics. Additionally, OBD may receive funding through research grants and partnerships aimed at advancing epigenetic research, which further contributes to its earnings. Strategic collaborations with industry leaders enhance its market presence and facilitate revenue growth.

Oxford BioDynamics Financial Statement Overview

Summary

Oxford BioDynamics faces substantial financial challenges with consistent net losses, rising leverage, and negative cash flows. Although there are some assets and equity, these are diminishing, indicating potential liquidity and solvency concerns.

Income Statement

Oxford BioDynamics shows a challenging financial trajectory with consistent net losses over the past years. The gross profit margin is low, and net income has been negative, indicating unprofitability. Revenue growth has been erratic, with no clear upward trend. EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet presents concerns, particularly in rising debt levels relative to equity, which has led to a rising debt-to-equity ratio. Return on equity is negative due to consistent net losses, and the equity ratio has decreased, indicating increased leverage and financial risk. However, there is still some equity cushion available, albeit shrinking.

Cash Flow

Cash flow analysis indicates significant strains with negative free cash flow and operating cash flow over the years. There was a notable decline in free cash flow growth rate, highlighting cash generation issues. Operating cash flow to net income ratio is negative, reinforcing operational cash challenges. Financing activities have been critical in supporting cash needs.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	617.00K	636.00K	510.00K	154.00K	341.00K	456.00K
Gross Profit	-7.49M	289.00K	266.00K	116.00K	-557.00K	-166.00K
EBITDA	-9.32M	-10.27M	-9.84M	-6.16M	-6.43M	-4.42M
Net Income	-11.11M	-11.57M	-10.83M	-6.71M	-6.68M	-4.31M
Balance Sheet
Total Assets	11.07M	12.11M	16.13M	11.34M	15.38M	15.35M
Cash, Cash Equivalents and Short-Term Investments	1.19M	2.83M	5.25M	999.00K	4.34M	11.51M
Total Debt	6.00M	5.74M	6.44M	6.14M	6.59M	541.00K
Total Liabilities	9.44M	7.75M	10.07M	8.76M	8.69M	1.77M
Stockholders Equity	1.62M	4.36M	6.05M	2.59M	6.68M	13.56M
Cash Flow
Free Cash Flow	-7.46M	-10.77M	-9.01M	-6.08M	-9.01M	-3.86M
Operating Cash Flow	-6.71M	-10.17M	-8.29M	-5.18M	-5.92M	-3.40M
Investing Cash Flow	1.68M	-1.49M	-691.00K	1.25M	2.83M	4.58M
Financing Cash Flow	5.03M	8.25M	13.42M	2.56M	-804.00K	-181.00K

Oxford BioDynamics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.42 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.46, and below the 200-day MA of 0.59, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.03 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.

Oxford BioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	64 Neutral	£11.12M	―	-13.85%	―	7.27%	39.64%
AREC	63 Neutral	£27.37M	―	-137.62%	―	10.50%	-9.60%
Sector *	51 Neutral	$8.02B	-0.39	-43.38%	2.20%	22.34%	-2.13%
APTA	46 Neutral	£29.67M	―	-99.43%	―	17.39%	96.02%
OBD	44 Neutral	£8.32M	―	-333.59%	―	45.22%	55.71%
HEMO	―	£43.75M	―	-302.41%	―	―	―
FAB	44 Neutral	£18.18M	―	-139.16%	―	72.98%	55.36%

Oxford BioDynamics Corporate Events

Oxford BioDynamics’ EpiSwitch CiRT Test Shows Promise in Clinical Treatment Decisions

Oxford BioDynamics has announced interim results from its PROWES trial, showcasing the clinical utility of its EpiSwitch CiRT test in guiding treatment decisions for patients undergoing immune checkpoint inhibitor therapy. The study, published in the journal Cancers, demonstrated that the CiRT test influenced treatment choices in 61% of cases, helping oncologists make more informed decisions. The test’s ability to predict patient responses with high sensitivity and specificity could lead to significant cost savings by avoiding ineffective treatments. The company plans to apply for inclusion in the US National Comprehensive Cancer Network clinical guidelines, aiming for broader adoption and commercial success.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Partners with Google Cloud to Advance Genomic Analytics

Oxford BioDynamics has announced a collaboration with Google Cloud to enhance its cloud-based analytical frameworks for precision medicine. This partnership will allow OBD to scale its EpiSwitch® platform using Google Cloud’s infrastructure, facilitating high-throughput, AI-powered 3D genomic analytics. The collaboration is expected to improve OBD’s digital transformation, enabling faster insights and broader access for its pharmaceutical and biotech partners, while also creating opportunities for future commercialization of its platform.

Oxford BioDynamics Sees Shift in Shareholder Structure

Oxford BioDynamics PLC has announced a significant change in its shareholder structure following the acquisition of financial instruments by Trafalgar Capital Management (HK) Limited. This acquisition has resulted in Trafalgar Capital holding 3.3% of the voting rights in Oxford BioDynamics, marking a notable shift in the company’s ownership landscape. This development could potentially impact the company’s strategic decisions and influence its market position, as it reflects increased interest and investment from international stakeholders.

Oxford BioDynamics and Agilent Technologies to Showcase EpiSwitch 3D Genomic Platform

Oxford BioDynamics announced a joint webinar with Agilent Technologies to showcase their EpiSwitch 3D Genomic Platform, which utilizes Agilent’s SureScan microarray to explore 3D genome architecture for disease insights. This collaboration has been crucial in developing accurate and scalable clinical tests, such as the EpiSwitch PSE for prostate cancer detection and the EpiSwitch SCB for diagnosing canine cancers, enhancing the company’s position in precision medicine.

Oxford BioDynamics Announces Change in Major Holdings

Oxford BioDynamics PLC announced a change in major holdings as Spreadex LTD adjusted its financial instruments, resulting in a slight decrease in its overall voting rights in the company. This adjustment reflects a minor shift in stakeholder positions, potentially impacting the company’s governance dynamics and signaling strategic financial maneuvers within the biotechnology sector.

Oxford BioDynamics Announces Change in Major Holdings

Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring a significant portion of financial instruments, resulting in a total voting rights percentage of 3.0815%. This acquisition reflects Spreadex’s strategic interest in the company, potentially impacting Oxford BioDynamics’ market positioning and shareholder dynamics.

Oxford BioDynamics’ EpiSwitch Biomarkers Show Promise in Cancer Diagnostics

Oxford BioDynamics announced the successful use of its EpiSwitch blood-based biomarkers in a study conducted by Pfizer, which evaluated tumor status and treatment outcomes in cancer patients from the JAVELIN Bladder 100 Trial. The study demonstrated that EpiSwitch biomarkers can effectively determine immune activity levels in tumors, aiding in cancer treatment decisions and potentially revolutionizing cancer detection and monitoring. This advancement underscores the company’s potential for growth in the cancer diagnostics market and highlights the efficacy of its EpiSwitch technology, already proven in prostate cancer testing.

Oxford BioDynamics Announces Changes in Major Holdings

Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring or disposing of financial instruments, resulting in a shift in voting rights. This notification reflects a slight decrease in the total percentage of voting rights held by Spreadex, which may influence the company’s shareholder dynamics and strategic decisions moving forward.

Oxford BioDynamics Reports Strong Interim Results and Strategic Progress

Oxford BioDynamics Plc announced its interim results for the six-month period ending March 31, 2025, highlighting significant corporate and operational achievements. The company reported a substantial increase in revenue and cash reserves, driven by the growth in sales of its EpiSwitch PSE test and strategic agreements, such as the one with Bupa UK. Despite ongoing commercial discussions, no definitive deals have been secured, prompting the company to focus on preserving business integrity and optimizing shareholder value. The company also achieved ISO15189 accreditation for its UK lab and recorded its highest PSE sales in June 2025, indicating strong market acceptance and potential for future growth.

Oxford BioDynamics Sees Change in Financial Instrument Holdings

Oxford BioDynamics PLC has announced a change in its financial instrument holdings, as Spreadex LTD has adjusted its position in the company. The notification indicates that Spreadex now holds a total of 3.0049% of the voting rights in Oxford BioDynamics, reflecting a slight increase from its previous position. This adjustment may influence the company’s market dynamics and stakeholder interests as it continues to navigate the competitive landscape of the biotechnology sector.